| Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: a randomized trial IM Jacobson, RS Brown Jr, B Freilich, N Afdhal, PY Kwo, J Santoro, ... Hepatology 46 (4), 971-981, 2007 | 389 | 2007 |
| Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy T Poynard, M Colombo, J Bruix, E Schiff, R Terg, S Flamm, ... Gastroenterology 136 (5), 1618-1628. e2, 2009 | 336 | 2009 |
| Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up MD Cappellini, M Bejaoui, L Agaoglu, D Canatan, M Capra, A Cohen, ... Blood, The Journal of the American Society of Hematology 118 (4), 884-893, 2011 | 252 | 2011 |
| A phase 1/2, dose‐escalation trial of deferasirox for the treatment of iron overload in HFE‐related hereditary hemochromatosis P Phatak, P Brissot, M Wurster, PC Adams, HL Bonkovsky, J Gross, ... Hepatology 52 (5), 1671-1779, 2010 | 147 | 2010 |
| Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C J Bruix, T Poynard, M Colombo, E Schiff, K Burak, EJL Heathcote, T Berg, ... Gastroenterology 140 (7), 1990-1999, 2011 | 146 | 2011 |
| Impact of weight‐based ribavirin with peginterferon alfa‐2b in African Americans with hepatitis C virus genotype 1 IM Jacobson, RS Brown Jr, J McCone, M Black, C Albert, MS Dragutsky, ... Hepatology 46 (4), 982-990, 2007 | 101 | 2007 |
| Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years Y Deugnier, B Turlin, M Ropert, MD Cappellini, JB Porter, V Giannone, ... Gastroenterology 141 (4), 1202-1211. e3, 2011 | 90 | 2011 |
| Long‐term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron‐overloaded patients with sickle cell disease E Vichinsky, F Bernaudin, GL Forni, R Gardner, K Hassell, MM Heeney, ... British journal of haematology 154 (3), 387-397, 2011 | 87 | 2011 |
| Cyclosporine therapy in inflammatory bowel disease: short-term and long-term results SR Gurudu, LH Griffel, RJ Gialanella, KM Das Journal of clinical gastroenterology 29 (2), 151-154, 1999 | 60 | 1999 |
| Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R Study, a US community based … IM Jacobson, RS Brown, B Freilich, N Afdhal, P Kwo, J Santoro, S Becker, ... Hepatology 42 (4), 749A-749A, 2005 | 57 | 2005 |
| Gastric intestinal metaplasia as detected by a monoclonal antibody is highly associated with gastric adenocarcinoma ZK Mirza, KK Das, J Slate, RN Mapitigama, PS Amenta, LH Griffel, ... Gut 52 (6), 807-812, 2003 | 50 | 2003 |
| Use of a novel monoclonal antibody in diagnosis of Barrett's esophagus LH Griffel, PS Amenta, KM Das Digestive diseases and sciences 45, 40-48, 2000 | 48 | 2000 |
| Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II) S Zeuzem, R Flisiak, JM Vierling, W Mazur, G Mazzella, S Thongsawat, ... Alimentary Pharmacology & Therapeutics 42 (7), 829-844, 2015 | 47 | 2015 |
| The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease KD Glazier, AL Palance, LH Griffel, KM Das Journal of clinical gastroenterology 39 (1), 21-26, 2005 | 47 | 2005 |
| 988 sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa interferon/ribavirin (I/R) nonresponders (NR): Final results … T Poynard, E Schiff, R Terg, RM Otero, S Flamm, W Schmidt, T Berg, ... Journal of hepatology 48, S369-S369, 2008 | 41 | 2008 |
| 49 PEGINTRON MAINTENANCE THERAPY IN CIRRHOTIC (METAVIR F4) HCV PATIENTS, WHO FAILED TO RESPOND TO INTERFERON/RIBAVIRN (IR) THERAPY: FINAL RESULTS OF THE EPIC3 CIRRHOSIS … J Bruix, T Poynard, M Colombo, E Schiff, J Reichen, K Burak, ... Journal of hepatology 50, S22-S22, 2009 | 40 | 2009 |
| Liver safety assessment in special populations (hepatitis B, C, and oncology trials) GA Kullak-Ublick, M Merz, L Griffel, N Kaplowitz, PB Watkins Drug safety 37, 57-62, 2014 | 29 | 2014 |
| Prevalence of mabDAS-1 positivity in biopsy specimens from the esophagogastric junction C Rogge-Wolf, CA Seldenrijk, KM Das, R Timmer, R Breumelhof, ... Official journal of the American College of Gastroenterology| ACG 97 (12 …, 2002 | 25 | 2002 |
| FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program T Poynard, M Munteanu, M Colombo, J Bruix, E Schiff, R Terg, S Flamm, ... Journal of hepatology 54 (2), 227-235, 2011 | 24 | 2011 |
| 41 Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the Win-R trial RS Brown, IM Jacobson, N Afdhal, B Freilich, MP Pauley, F Regenstein, ... Journal of Hepatology, S20, 2006 | 17 | 2006 |
Poynard TAPHP UPMC INSERM BioPredictiveVerifierad e-postadress på poynard.com
